Detecting Transthyretin Cardiac Amyloidosis With Artificial Intelligence

How well does an artificial intelligence (AI)–augmented screening program detect transthyretin cardiac amyloidosis (ATTR-CM)?In this nonrandomized clinical trial conducted at multiple sites in a large health system, an AI model identified 1471 patients as positive for potential ATTR-CM, with 256 patients meeting study criteria and eligible for trial inclusion. On physician notification, 50 patients underwent further diagnostic testing, and ATTR-CM was diagnosed in 24 (48%), with treatment initiated in 21 patients (88%).AI-augmented clinical programs may identify undiagnosed ATTR-CM and reduce diagnostic delays, but prospective randomized trials are needed to determine if outcomes are improved.

Corresponding Author: Timothy Poterucha, MD, Department of Cardiology, Mayo Clinic, 200 1st St SW Rochester, MN 55906 (poterucha.timothy@mayo.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.